215 related articles for article (PubMed ID: 9845119)
1. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
Wilson WR; Li AE; Cowan DS; Siim BG
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):905-8. PubMed ID: 9845119
[TBL] [Abstract][Full Text] [Related]
2. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Siemann DW; Overgaard J; Horsman MR
Radiat Res; 2001 Nov; 156(5 Pt 1):503-9. PubMed ID: 11604063
[TBL] [Abstract][Full Text] [Related]
3. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
4. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
[TBL] [Abstract][Full Text] [Related]
5. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
Siim BG; Laux WT; Rutland MD; Palmer BN; Wilson WR
Cancer Res; 2000 Aug; 60(16):4582-8. PubMed ID: 10969810
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
[TBL] [Abstract][Full Text] [Related]
7. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036
[TBL] [Abstract][Full Text] [Related]
8. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
9. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
10. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Philpott M; Baguley BC; Ching LM
Cancer Chemother Pharmacol; 1995; 36(2):143-8. PubMed ID: 7767951
[TBL] [Abstract][Full Text] [Related]
11. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
[TBL] [Abstract][Full Text] [Related]
12. DMXAA: an antivascular agent with multiple host responses.
Baguley BC; Ching LM
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1503-11. PubMed ID: 12459378
[TBL] [Abstract][Full Text] [Related]
13. Combination of vascular targeting agents with thermal or radiation therapy.
Horsman MR; Murata R
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1518-23. PubMed ID: 12459380
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Overgaard J; Horsman MR
Int J Hyperthermia; 2001; 17(6):508-19. PubMed ID: 11719967
[TBL] [Abstract][Full Text] [Related]
15. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
[TBL] [Abstract][Full Text] [Related]
16. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S; Kestell P; Baguley BC; Paxton JW
Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
[TBL] [Abstract][Full Text] [Related]
17. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
[TBL] [Abstract][Full Text] [Related]
18. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
19. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
